Related Experiment Video

Updated: Jun 19, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Novel antiangiogenic agents in the treatment of refractory renal cell carcinoma

Guru Sonpavde1, Thomas E Hutson

  • 1Texas Oncology, Houston, TX, USA.

Clinical Genitourinary Cancer
|November 7, 2009
PubMed

Insights

New therapies like sunitinib and sorafenib have improved renal cell carcinoma (RCC) management. However, these treatments are not curative, necessitating further research into novel antiangiogenic agents and combinations for better outcomes.

Area of Science:

  • Oncology
  • Medical treatments

Background:

  • Sunitinib, sorafenib, and temsirolimus have transformed renal cell carcinoma (RCC) treatment.
  • Bevacizumab and interferon-alpha combination therapy is gaining regulatory attention.
  • Everolimus has shown improved outcomes after first-line tyrosine kinase inhibitors (TKIs).

Purpose of the Study:

  • To review the current landscape of antiangiogenic therapies for renal cell carcinoma.
  • To highlight the limitations of existing treatments and the need for more effective options.
  • To discuss emerging novel antiangiogenic agents and combination strategies.

Main Methods:

  • Review of recent clinical trials and regulatory approvals.
  • Analysis of novel therapeutic agents targeting angiogenesis in RCC.
  • Evaluation of combination therapies in advanced renal cell carcinoma.

Main Results:

  • Several targeted therapies have significantly improved outcomes in renal cell carcinoma.
  • Novel antiangiogenic agents, including TKIs and monoclonal antibodies, are under investigation.
  • Emerging combination therapies show promise for enhanced efficacy.

Conclusions:

  • Current antiangiogenic therapies offer improved outcomes but are not curative for renal cell carcinoma.
  • Continued development of novel agents and combinations is crucial for advancing RCC treatment.
  • The expanding therapeutic armamentarium offers hope for better patient outcomes in renal cell carcinoma.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...